Colin Hill is CEO of Aitia Bio, which he co-founded in 2000. In 2020 the company launched the world’s first Virtual Patients, beginning in multiple myeloma and followed by prostate cancer and Alzheimer’s disease. Hill serves on the board of Centrexion Therapeutics, previously served on the boards of Biotelemetry and PPD, and was a founding member of the boards of AesRx and of TMed (Transforming Medicine: The Elizabeth Kauffman Institute). In 2016, he was appointed to the Massachusetts Digital Health Council. Hill was founding chairman of O’Reilly Media’s Strata Rx in 2012. In 2004, Hill was named to MIT Technology Review’s Innovators Under 35. He has appeared in The Wall Street Journal, Nature, The Boston Globe, Politico, Forbes, Wired, The Economist, and other publications and media outlets.
Previously
During the COVID-19 pandemic, the Atlantic lambasted the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Tol...